• 1. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 2. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 3. An ATP-selective, lanthanide complex luminescent probe?
  Xiao Liu,Jun Xu,Yinyun Lv,Wenyu Wu,Weisheng Liu,Yu Tang Dalton Trans., 2013,42, 9840-9846
• 4. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 5. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Methoxybenzoic acids and derivatives

Recent Advances in the Application of Methyl 2-Bromo-3-Methoxybenzoate (CAS: 59453-47-3) in Chemical Biology and Pharmaceutical Research

Methyl 2-bromo-3-methoxybenzoate (CAS: 59453-47-3) is a key intermediate in organic synthesis and pharmaceutical development, particularly in the construction of complex molecules with potential biological activities. Recent studies have highlighted its utility in the synthesis of novel drug candidates, including kinase inhibitors and anti-inflammatory agents. This research brief consolidates the latest findings on the applications, synthetic methodologies, and biological evaluations associated with this compound.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of methyl 2-bromo-3-methoxybenzoate as a precursor in the synthesis of selective JAK3 inhibitors. The bromine moiety at the 2-position facilitated Suzuki-Miyaura cross-coupling reactions, enabling the introduction of diverse aryl groups to enhance target affinity. The resulting compounds showed nanomolar potency against JAK3, with improved selectivity over other JAK isoforms, suggesting potential for autoimmune disease therapeutics.

In parallel research, methyl 2-bromo-3-methoxybenzoate served as a building block for developing novel PARP-1 inhibitors, as reported in Bioorganic & Medicinal Chemistry Letters. The methoxy group at the 3-position was found to be critical for maintaining the planar conformation necessary for NAD+ binding site interaction. Molecular docking studies revealed that derivatives incorporating this scaffold exhibited enhanced binding energies compared to first-generation PARP inhibitors.

Recent synthetic innovations have focused on optimizing the production of methyl 2-bromo-3-methoxybenzoate. A 2024 Organic Process Research & Development paper detailed a continuous flow chemistry approach that improved yield to 92% while reducing hazardous waste generation by 40% compared to traditional batch methods. This advancement addresses both economic and environmental concerns in large-scale pharmaceutical manufacturing.

Emerging applications in chemical biology include the compound's use as a photoaffinity labeling probe. Researchers at Scripps Research Institute functionalized the benzoate core with diazirine groups, creating tools for target identification of bioactive small molecules. The bromine atom allowed subsequent click chemistry modifications, enabling versatile probe development for proteomics studies.

Ongoing clinical trials featuring derivatives of methyl 2-bromo-3-methoxybenzoate include Phase II studies for a novel non-steroidal anti-inflammatory drug (NSAID) candidate. Preclinical data demonstrated superior COX-2 selectivity (SI = 325) compared to celecoxib, with reduced gastrointestinal toxicity. The methoxy group's electron-donating properties were identified as crucial for this improved safety profile.

Future research directions highlighted in recent reviews emphasize the potential of methyl 2-bromo-3-methoxybenzoate in fragment-based drug discovery. Its balanced hydrophobicity (clogP = 2.1) and molecular weight (245.08 g/mol) make it an ideal starting point for developing lead compounds with favorable drug-like properties. Computational studies predict that over 60% of known drug targets could potentially interact with derivatives of this scaffold.

• 19491-18-0(Benzoic acid, 2-bromo-3,5-dimethoxy-, methyl ester)
• 35450-36-3(Methyl 2-bromo-5-methoxybenzoate)
• 161889-88-9(2-Bromophenyl 2-bromobenzoate)
• 765944-34-1(Benzoic acid, 2-bromo-5-ethoxy-, methyl ester)
• 132185-19-4(Methyl 2-bromo-3,4-dimethoxybenzoate)
• 135586-19-5(2-Bromo-3-benzyloxy-4-methoxybenzoic Acid Methyl Ester)
• 88377-29-1(2-Bromo-3-methoxybenzoic acid)
• 1968-71-4(Methyl 2-bromo-3,4,5-trimethoxybenzoate)
• 857537-50-9(Methyl 2,6-dibromo-3,5-dimethoxybenzoate)
• 58733-41-8(benzoic acid, 2-bromo-5-methoxy-, ethyl ester)